Active Investment: When the Path Is Not Straight

April 2026

 

A sailboat does not fail its voyage the moment it drifts off course. The wind shifts, the current pulls, and the waves can push the boat off its bearing. An inexperienced captain may treat every deviation as a sign of disaster, fighting the conditions and risking far worse in the process.

A seasoned captain knows that this is precisely when judgment matters most. He does not ignore the conditions, nor does he fight them blindly. He adapts, resets his bearing and asks the question that matters most: has the destination become unreachable, or has the route simply become less direct? That judgment, knowing the difference between a temporary drift and a voyage that truly must be reconsidered, is what separates losing control of the journey from navigating it well.

We believe investing requires much the same discipline. New information, and the market’s reaction to it, can create share price volatility that is sudden, severe and unsettling. Our job is not to borrow the market’s emotions or outsource our judgment to its latest interpretation. It is to decide whether new information has altered the path by which a business may realize its long-term earnings potential, or whether it has genuinely changed the thesis we originally underwrote. That long-term lens, and the discipline it demands, sits at the core of Pembroke’s investment approach.

During the past twelve months, two holdings tested that discipline in very different ways. Champion Iron, a producer of high-purity iron ore concentrate in northern Québec, spent the year with its share price tethered to the commodity cycle, as the market treated it like a generic iron ore name and looked past the growth thesis underneath. Globus Medical, a spine-led medical device company, faced a different challenge: the market questioned whether a management team with a strong record had made a strategic misstep with a recent acquisition.

The industries were different. The pattern was familiar. In both cases, the question was the same: had the destination changed, or only the path?

WHAT IT LOOKED LIKE FROM THE OUTSIDE

Both stocks experienced sharp, at times confusing volatility. Champion’s share price travelled a wide arc, only to end the period not far from where it began. At various moments, the market fixated on softer iron ore pricing, operating issues at the mine, questions around a large investment in higher-grade production capacity, rail disruptions and the terms of a foreign acquisition. Each concern arrived with force. Few endured for long.

Globus followed a similarly uneven route: a sharp spring de-rating, a dramatic autumn re-rating and then a late-quarter pullback. Along the way, the market cycled through anxiety about an acquisition, doubts about the core business, a chief executive officer transition, and broader pressure across the medical device sector.

From the outside, both looked like situations that demanded constant reaction. From the inside, very little pointed to the need for one.

CHAMPION IRON: A GROWTH CYCLICAL IN COMMODITY CLOTHING

Champion is often described as an iron ore miner. That is true, but it is not the most useful way to understand the business. What matters is that the company produces high-purity material today and is investing to move further up the quality curve. This product is scarce, earns a premium to the generic benchmark and may become more valuable over time as steelmakers shift toward higher-grade inputs. That scarcity, not the daily mood of the iron ore market, is the real reason to own the business over a four-year period.

The spring of 2025 brought real operational disappointment. A change in the mining sequence exposed lower grade and harder rock than expected, which weighed on recovery and unit costs. Those were not imaginary concerns. Ore hardness was a real cost. The upgrade to the company’s processes also carried genuine questions around budget and timing. In addition, commodity pricing was outside management’s control.

However, our work is not to wave away risk. It is to weigh the probability and significance of that risk against the four-year outlook. The thesis had never rested on one section of the ore body. Management adjusted. The upgrade remained on track. The long-term product advantage remained intact. We increased exposure in late spring when the market had become consumed by the near-term negatives.

Later, the market grew impatient with the absence of a long-term contract for the higher-grade product. We took some comfort from a management team willing to disappoint short-term traders rather than negotiate for the sake of appearing busy. The valuation was not demanding, and nothing in the developing picture suggested fresh impairment. Holding was the decision. In investing, this is still a decision, even when it leaves no footprint on a trade blotter.

GLOBUS MEDICAL: TRUST EARNED, THEN TESTED AGAIN

Globus presented a different problem, and in some ways a more subtle one. Management had already integrated NuVasive, a much larger acquisition that the market had initially greeted with much the same scepticism it directed more recently at Nevro. That earlier deal had produced more value than many expected. So when Globus acquired Nevro, a smaller, cheaper and more opportunistic transaction in an adjacent category, the market was asking a question we had effectively confronted before: do we trust this management team’s capital-allocation judgment?

At Pembroke, we did, but for specific reasons. Management was not arguing that Nevro was a wonderful business as it stood. The thesis was more pragmatic: Globus believed it could take a cheaply acquired asset, improve its economics and create value even if revenue did not grow much in the near term. If the experiment failed, management also believed it had the discipline to shut it down.

Overall, the lowered near-term earnings guidance reflected carrying costs, not a broken trajectory. That distinction mattered. The market was fixated on dilution to the next set of numbers. We were more interested in whether a proven operator was once again being underestimated.

The third-quarter release in November provided the confirmation that the market had been waiting for. Growth in the United States for spine-related products had been accelerating. Nevro had achieved target profitability much sooner than expected. Full-year guidance had increased meaningfully. The transition of the chief executive officer had also been handled smoothly. The successor was an experienced insider, and the founder remained closely involved as executive chairman.

We added to the position on the November release. Our confidence in the business was higher than it had been six months earlier, not lower.

WHAT THIS SAYS ABOUT OUR APPROACH

Neither Champion nor Globus fits neatly into the category of winner or loser. Over the past twelve months, both tested whether we could distinguish between developments that warranted action and noise that did not.

Much of the Pembroke investment team’s work does not result in trades. A decision to hold through scepticism or not to trim simply because a share price has risen remains a decision. Such decisions require judgment about whether a market move reflects new information or simply a different time horizon from our own.

The easiest critique in investing is the retrospective one. After the fact, it is always possible to identify the trade that would have added value. What is harder, and in our view more important over time, is to remain consistent when the evidence is incomplete and the temptation to react is strongest. Sometimes that looks like quiet inaction. Clients may not realize it, but more often than not, it is exactly the job.

 

Back to Top of Page

Other Articles Of Interest